Allergan launches generic version of AstraZeneca cholesterol tablet

Pharmaceutical company Allergan has received approval from the US Food and Drug Administration to launch a generic version of a cholesterol drug owned by AstraZeneca.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

AstraZeneca completes acquisition of Takeda’s respiratory business

5 May 2016 AstraZeneca has completed its acquisition of pharmaceutical company Takeda’s respiratory business.

Americas

FTC sues Endo over ‘pay-for-delay’ settlements

4 April 2016 The Federal Trade Commission has sued Endo Pharmaceuticals for allegedly violating competition laws by agreeing to so-called pay-for-delay settlements surrounding the launch of generic versions of two drugs.

Americas

Acorda and AstraZeneca claim victory over Mylan

21 March 2016 The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Allergan launches generic version of AstraZeneca cholesterol tablet

More on this story

Editor's picks

Editor's picks

More features